Nalbuphine Serb (Nalbuphine Hydrochloride)

Nalbuphine works by activating kappa opioid receptors, which produce analgesia, while simultaneously blocking mu opioid receptors. This dual action provides pain relief and creates a ceiling effect for respiratory depression, reducing the risk of severe respiratory compromise compared with pure mu‑agonists.

The appropriate dose of Nalbuphine Serb is determined by the prescribing clinician based on the patient’s pain severity, clinical condition, route of administration, and individual response. No fixed regimen is provided here; dosing must follow the prescriber’s judgment and local guidelines.

Safety data for Nalbuphine Serb in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Nalbuphine Serb, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike morphine, which is a pure mu‑opioid receptor agonist, nalbuphine combines kappa agonism with mu antagonism. This results in effective analgesia with a lower ceiling for respiratory depression, making it a useful alternative when respiratory safety is a primary concern.

Nalbuphine Serb should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Nalbuphine Serb is administered by a healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route and rate of injection are selected according to the clinical situation and the prescriber’s instructions.

Serious risks include respiratory depression, severe hypotension, allergic reactions such as anaphylaxis, and profound sedation. Patients should be monitored closely for these events, especially when receiving high doses or when combined with other central nervous system depressants.

Nalbuphine Serb should be avoided in individuals with known hypersensitivity to nalbuphine or any component of the formulation, in patients with uncontrolled severe respiratory disease, and in those for whom opioid antagonism may precipitate withdrawal or interfere with required analgesia.